- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03922373
A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects
The Single-dose and Multiple-dose Pharmacokinetic Study of Benzonatate Soft Capsule in Chinese Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Kun Lou
- Phone Number: 0311-67808817
- Email: loukun@mail.ecspc.com
Study Locations
-
-
Hebei
-
Shijiazhuang, Hebei, China, 050000
- Recruiting
- Cspc Nbp Pharmaceutical.Co.Ltd
-
Contact:
- Kun Lou
- Phone Number: 0311-67808817
- Email: loukun@mail.ecspc.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. You should fully understand the testing content, process and adverse reaction. Freely given informed consent.
2. Male or Female ages 18 through 45 (include 18 and 45).
3. The male subjects weighed more than 50 kg, the female subjects weighed more than 45kg. Body Mass Index(BMI) between 18 and 28, BMI=Weight(kg)/Height2(m2).
Exclusion Criteria:
1. Allergy to benzonatate, allergic constitution (Allergic to a variety of medicines and foods).
2. Abnormal physical examination and abnormal vital signs, and have clinical significance.
3. Abnormal results of laboratory studies and have clinical significance. 4. Abnormal electrocardiogram and have clinical significance. 5. The hepatitis B surface antigen(HbsAg), hepatitis C antibody, HIV antibody and antigen, Treponema pallidum antibody(TP-Ab)were positive.
6. Patients with cardiovascular system, urinary system, digestive system, nervous system, respiratory system, mental or immunodeficiency diseases.
7. Dysphagia or with gastrointestinal history influencing drug absorption. 8. Patients with any diseases that increase the risk of bleeding (e.g. acute gastritis, duodenal ulcer, and so on).
9. Patients smoked more than 5 cigarettes a day in the first 3 months of screening 10. Alcohol breath test were positive (blood-alcohol concentration>0.0mg/100ml) , or have history of alcoholism (more than 14 units of alcohol every week, 1 unit is equal to 285ml of beer, 25ml of spririts, or 100ml of wine.
11. Drug abuse screening were positive by urinalysis, or have a history of substance abuse or taken drugs last 3 years.
12. Subjects (or his fere) have family planning in the next 3 months, or can't take effective contraceptive measures in the next 3 months.
13. Female subjects during lactation, the quantitative of β-HCG exceed the upper limit of normal range.
14. Donate blood or massive blood loss (>450ml) in the first 3 months of screening.
15. Taken any drugs that can inhibit the activity of liver enzyme in the first 28 days of screening, or taken the inhibitor or inducer of CYP3A4, P-gp, Bcrp, such as Itraconazole, Ketoconazole, Dronedarone.
16. Taken any prescription drugs, OTC, vitamin products or Chinese herbal medicine in the first 14 days of screening.
17. Special diets (e.g. pitaya, mango, pomelo) or strenuous exercise in the first 14 days of screening, or other factors to influence drug absorption, distribution, metabolism and excretion.
18. Have attended clinical trial in the first 3 months of screening 19. The patient can't finish the study according to protocol requirements. 20. Acute disease or simultaneous medication between screening stage and the first time taking study drugs.
21. Have consumed any alcoholic or caffeinated food or beverage such as chocolate and coffee in the first 48 hours of taking the study drug.
22. Investigator believes other factors not suitable for testing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Benzonatate
|
Subjects in group A will be given benzonatate 100mg once after a 10-hour fast in the first day of the trail
Subjects in group B will be given benzonatate 200mg once after a 10-hour fast in the first day of the trail, and they will be given benzonatate 200mg thrice in the second and third day of the trail, in the fourth day, they will be given benzonatate 200mg once after a 10-hour fast.
Subjects in group C will be given benzonatate 400mg once after a 10-hour fast in the first day of the trail
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: day 1 and day 4
|
Time to peak
|
day 1 and day 4
|
Cmax
Time Frame: day 1 and day 4
|
peak plasma concentration
|
day 1 and day 4
|
t1/2
Time Frame: day 1 and day 4
|
elimination half-life time
|
day 1 and day 4
|
AUC0-t
Time Frame: day 1 and day 4
|
Area under the plasma concentration versus time curve from the medication to the last time the concentration can be measured
|
day 1 and day 4
|
AUC0-∞
Time Frame: day 1 and day 4
|
Area under the plasma concentration versus time curve from the medication extrapolate the infinity time
|
day 1 and day 4
|
CL/F
Time Frame: day 1 and day 4
|
elimination ratio
|
day 1 and day 4
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yang Lin, M.D., Beijing Anzhen Hospital
- Principal Investigator: Shan Jing, M.D., Beijing Anzhen Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EY20170502
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cough
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Respivant Sciences GmbHRespivant Sciences Inc.TerminatedChronic Cough | IPF | Persistent Cough in IPFUnited States, United Kingdom, Netherlands, Australia, Belgium, New Zealand, Turkey, Italy, Germany, Czechia, Canada
-
The First Affiliated Hospital of Zhejiang Chinese...Completed
-
ILiAD BiotechnologiesCompletedPertussis/Whooping Cough | Bordetella Pertussis, Whooping CoughUnited Kingdom
-
KK Women's and Children's HospitalSingapore University of Technology and DesignUnknownCough | URTI | Cough Variant Asthma | Cough; Bronchial, With Grippe or InfluenzaSingapore
-
Shanghai Zhongshan HospitalNot yet recruitingSufentanil-induced Cough
-
Merck Sharp & Dohme LLCCompletedChronic CoughCanada, Czechia, Denmark, Hungary, Peru, Poland, Ukraine, United Kingdom, United States, Australia, China, Colombia, Germany, Guatemala, Israel, Italy, Malaysia, New Zealand, South Africa, Turkey
-
Khon Kaen UniversityCompleted
-
PhytoHealth CorporationCompleted
Clinical Trials on Group A: Benzonatate 100mg
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...Active, not recruiting
-
Galapagos NVCompleted
-
Chong Kun Dang PharmaceuticalCompletedDyslipidemiaKorea, Republic of
-
Riphah International UniversityCompletedAutism Spectrum DisorderPakistan
-
The University of Texas Health Science Center,...National Institute for Occupational Safety and Health (NIOSH/CDC)Completed
-
Kahramanmaras Sutcu Imam UniversityCompletedPain | Interleukin | Vessels; VaricoseTurkey
-
Manuel RodríguezUnknownBrain IschemiaSpain
-
Zhu WeimingRecruiting
-
Oxford University Hospitals NHS TrustUniversity Hospital Southampton NHS Foundation Trust; University Hospital BirminghamCompletedAtrial Fibrillation | Cardiac ArrhythmiaUnited Kingdom
-
Riphah International UniversityCompleted